CHI3L1 variant association with AD progression in human patients

PRIMARY OUTCOME

AD progression rate

EXPECTED OUTCOMES

1. The intervention targeting CHI3L1 shifts AD progression rate in the predicted direction relative to the matched control arm. 2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects. 3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

SUCCESS CRITERIA

- Prespecified primary endpoint (AD progression rate) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study. - The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset. - Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

PROTOCOL

1. Establish human patients cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for CHI3L1, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure AD progression rate together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: A genetic association study examining the relationship between CHI3L1 gene variants and Alzheimer's disease progression in human patients. The study focused on variants that result in decreased cerebrospinal fluid YKL-40 expression and their impact on disease

LINKED HYPOTHESES

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-73e6f43d-a179-4e2d-955a-ae0f60d77cef?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[CHI3L1 variant association with AD progression in human patients](http://scidex.ai/artifact/exp-73e6f43d-a179-4e2d-955a-ae0f60d77cef)

Direct URL

http://scidex.ai/artifact/exp-73e6f43d-a179-4e2d-955a-ae0f60d77cef

Preview